5 Best Information Technology Stocks To Invest In 2014

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, IT services specialist Syntel (NASDAQ: SYNT  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Syntel and see what CAPS investors are saying about the stock right now.

Syntel facts

Headquarters (founded)

Troy, Mich. (1980)

Market Cap

$2.74 billion

Industry

Information technology services

Trailing-12-Month Revenue

$742.3 million

Top Long Term Stocks To Watch Right Now: Myriad Genetics Inc (MYGN)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

Companion Diagnostic Services and Other Revenue

! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Myriad Genetics (NASDAQ: MYGN  ) , a molecular diagnostics developer, jumped as much as 11% after the company published data from its Prolaris diagnostic test in the Journal of Urology.

• [By Jake L'Ecuyer]

  Myriad Genetics (NASDAQ: MYGN) was also up, gaining 13.04 percent to $39.74 after the Centers for Medicare & Medicaid Services updated pricing for the sequencing of the BRCA1 and BRCA2 genes.

• [By John Kell]

  Myriad Genetics Inc.(MYGN) said it has agreed to acquire Crescendo Bioscience Inc. for $270 million in cash as the biopharmaceutical company looks to expand into the high-growth autoimmune market. Shares climbed 12% to $30.35 premarket.

5 Best Information Technology Stocks To Invest In 2014: CDC Point SpA (CDC)

CDC Point SpA is an Italy-based company engaged in the information technology (IT) sector. The Company structures its business into two main sectors: Production and Distribution of IT, and Business Value-Added. Through the Production and Distribution of IT sector, it is active in the manufacture of consumer desktop personal computers, as well as in the distribution and retail of computer hardware; peripheral equipment and accessories, such as keyboards, monitors, webcams, card readers, audio systems, voice over Internet protocol (VoIP) accessories and routers, and software products. Through the Business Value-Added sector, it provides value added services and solutions, including voice over Internet protocol (VoIP) services; video surveillance and home automation technologies; software management and e-commerce solutions, and Web services, such as domain registering, hosting, server, email, positioning on search engines and Web marketing services. Advisors' Opinion:

• [By Canadian Value]

  (Mostly) Psychological��/p> The battle against ISIS in the Middle East. Ebola and the Centers for Disease Control (CDC): It appears that the Center is not prepared for disease control.

  All of this together resulted in stock market declines of 7-12% in a month, depending on which index you measure. The size of this ��orrection��was not unexpected, but the short time frame was unusual. On some days the forced selling appeared to feed on itself and bordered on panic liquidation. As I write this letter on 10/17, this selling has abated, at least for the time being. The good news is that we raised some cash coming into this period, and

• [By abirk]

  The people of America are becoming more and more health conscious as obesity is growing at a great pace. As per the Centers for Disease Control and Prevention (CDC), more than one third of US adults (35.7%) is obese. This point out the finger towards the fast-food industry as they are using trans fats (responsible for clogging arteries) in their products to make it more mouth watering.

5 Best Information Technology Stocks To Invest In 2014: Arcos Dorados Holdings Inc (ARCO)

Arcos Dorados Holdings Inc., incorporated on December 9, 2010, is a McDonald�� franchisee. As of December 31, 2010, the Company operated or franchised 1,755 McDonald��-branded restaurants, which represented 6.7% of McDonald�� total franchised restaurants globally. It operates McDonald��-branded restaurants under two different operating formats, Company-operated restaurants and franchised restaurants. As of December 31, 2010, of its 1,755 McDonald��-branded restaurants in the territories, 1,292 (or 74%) were Company-operated restaurants and 463 (or 26%) were franchised restaurants. It generates revenues from two sources: sales by Company-operated restaurants and revenues from franchised restaurants, which consist of rental income, which is based on the greater of a flat fee or a percentage of sales reported by franchised restaurants. As of December 31, 2010, it owned the land for 510 of its restaurants (totaling approximately 1.2 million square meters) and the buildings for all but 12 of its restaurants. It divides its operations into four geographical divisions: Brazil; the Caribbean division, consisting of Aruba, Curacao, French Guiana, Guadeloupe, Martinique, Puerto Rico and the United States Virgin Islands of St. Croix and St. Thomas; North Latin America division (NOLAD), consisting of Costa Rica, Mexico and Panama, and South Latin America division (SLAD), consisting of Argentina, Chile, Colombia, Ecuador, Peru, Uruguay and Venezuela. As of December 31, 2010, 35.1% of its restaurants were located in Brazil, 29.7% in SLAD, 27.1% in NOLAD and 8.1% in the Caribbean division. The Company conducts its business through its indirect, wholly owned subsidiary Arcos Dorados B.V.

Company-Operated and Franchised Restaurants

The Company operates its McDonald��-branded restaurants under two basic structures: Company-operated restaurants operated by the Company and franchised restaurants operated by franchisees. Under both operating alternatives the real estate location may ! either be owned or leased by the Company. It owns, fully manages and operates the Company-operated restaurants and retains any operating profits generated by such restaurants, after paying operating expenses and the franchise and other fees owed to McDonald�� under the Master Franchise Agreements (MFAs). In Company-operated restaurants, it assumes the capital expenditures for the building and equipment of the restaurant and, if it owns the real estate location, for the land as well. Under its franchise arrangements, franchisees provide a portion of the capital required by initially investing in the equipment, signs, seating and decor of their restaurants, and by reinvesting in the business over time. It is required by the MFAs to own the real estate or to secure long-term leases for franchised restaurant sites. It subsequently leases or subleases the property to franchisees.

In exchange for the lease and services, franchisees pay a monthly rent to the Company, based on the greater of a fixed rent or a certain percentage of gross sales. In addition to this monthly rent, it collects the monthly continuing franchise fee, which generally is 5% of the United States dollar equivalent of the restaurant�� gross sales, and pays these fees to McDonald�� pursuant to the MFAs. However, if a franchisee fails to pay its monthly continuing franchise fee, it remains liable for payment in full of these fees to McDonald��. As of December 31, 2010, it was engaged in several joint ventures, which collectively owned 24 restaurants, in Argentina, Chile and Colombia.

Restaurant Categories

The Company classifies its restaurants into one of four categories: freestanding, food court, in-store and mall stores. Freestanding restaurants are the type of restaurant, which have ample indoor seating and include a drive-through area. Food court restaurants are located in malls and consist of a front counter and kitchen and do not have their own seating area. In-store restaurants are part ! of a larg! er building and resemble freestanding restaurants, except for the lack of a drive-through area. Mall stores are located in malls like food court restaurants, but have their own seating areas. As of December 31, 2010, 808 (or 46.2%) of its restaurants were freestanding, 359 (or 20.5%) were food court, 265 (or 15.1%) were in-stores and 319 (or 18.2%) were mall stores. In addition, it has four non-traditional stores, such as food carts.

Reimaging

As of December 31, 2010, the Company had completed the reimaging of 308 of 1,569 restaurants. Many of the reimaging projects include the addition of McCafe locations to the restaurant. It has developed system-wide guidelines for the interior and exterior design of reimaged restaurants.

McCafe Locations and Dessert Centers

McCafe locations are stylish, separate areas within restaurants where customers can purchase a range of customizable beverages, including lattes, cappuccinos, mochas, hot and iced premium coffees and hot chocolate. As of December 31, 2010, there were 267 McCafe locations in the Territories, of which 12% were operated by franchisees. Argentina, with 71 locations, has McCafe locations, followed by Brazil, with 67 locations. In addition to McCafe locations, it has Dessert Centers. Dessert Centers operate from existing restaurants, but depend on them for supplies and operational support. As of December 31, 2010, there were 1,306 Dessert Centers in the Territories.

Product Offerings

The Company�� menus feature three tiers of products: affordable entry-level options, such as its Big Pleasures, Small Prices or Combo del Dia (Daily Extra Value Meal) offerings, core menu options, such as the Big Mac, Happy Meal and Quarter Pounder, and premium options, such as Big Tasty or Angus premium hamburgers and chicken sandwiches and low-calorie or low-sodium products, which are marketed through common platforms rather than as individual items. These platforms can be based on the ty! pe of pro! ducts, such as beef, chicken, salads or desserts, or on the type of customer targeted, such as the children�� menu.

Advisors' Opinion:

• [By Roberto Pedone]

  Arcos Dorados (ARCO) operates and franchises McDonald's restaurants in Latin America. This stock closed up 7.7% to $13.33 in Wednesday's trading session.

  Wednesday's Volume: 3.81 million
  
  Three-Month Average Volume: 856,761
  
  Volume % Change: 333%

  From a technical perspective, ARCO soared higher here back above both its 50-day moving average at $12.31 and its 200-day moving average at $12.86 with heavy upside volume. This move has now taken shares of ARCO out of its downtrend and the stock closed strong near the highs of the day. Shares of ARCO are now moving within range of triggering a near-term breakout trade. That trade will hit if ARCO manages to take out its intraday high of $13.42 and then once it clears more resistance at $14.35 with high volume.

  Traders should now look for long-biased trades in ARCO as long as it's trending above its 200-day at $12.86 or its 50-day at $12.31 and then once it sustains a move or close above those breakout levels with volume that hits near or above 856,761 shares. If that breakout triggers soon, then ARCO will set up to re-test or possibly take out its next major overhead resistance levels at $15.52 to its 52-week high at $16. Any high-volume move above those levels will then give ARCO a chance to tag $18 to $19.

• [By Rich Duprey]

  Latin American McDonald's franchisee�Arcos Dorados (NYSE: ARCO  ) announced today its second-quarter dividend of $0.0596�per share on its Class A and Class B stock, slightly lower than the steady rate of $0.0597 per share it's paid since 2011.

• [By Seth Jayson]

  Arcos Dorados Holdings (NYSE: ARCO  ) is expected to report Q1 earnings on April 30. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Arcos Dorados Holdings's revenues will grow 4.4% and EPS will decrease -58.3%.

5 Best Information Technology Stocks To Invest In 2014: Spdr S&P Homebuilders Etf (XHB)

SPDR S&P Homebuilders ETF (the Fund) seeks to replicate as closely as possible, before expenses, the performance of the S&P Homebuilders Select Industry Index (the Index). To accomplish this, the Fund utilizes a passive or indexing approach and attempts to approximate the investment performance of its Index, by investing in a portfolio of stocks intended to replicate the Index.

The S&P Homebuilders Select Industry Index seeks to provide a representation of the homebuilders��sub-industry portion of the S&P Total Market Index. The S&P TMI tracks all the United States common stocks regularly traded on the NYSE, American Stock Exchange, NASDAQ National Market and NASDAQ Small Cap Exchanges. The Homebuilders Index is an equal weighted market cap index.

Advisors' Opinion:

• [By Jon C. Ogg]

  1. The U.S. economy grows 3% as housing starts surpass one million and private employment hits an all-time high – All time high on private employment? 1 million housing starts?

  Homebuilder ETF: SPDR S&P Homebuilders ETF (NYSEArca: XHB) as it is tied to homebuilders and building products rather than including other sectors that only overlap in building. At $32.57, its 52-week range is 426.94 to $33.38. Housing Starts were always well over 1 million on an annualized basis each month before the recession, but they only reached that in two months of 2013 (St. Louis Fed data).

  2. 10-Year Treasury yields move toward 3.5% as the Federal Reserve completes tapering and holds short-term rate near zero – This may sound bad, but it is actually good and fits in line with rates not rising too much. Keep in mind that the 10-year Treasury is at 2.94% now and ended at 3.03% on the last day of 2013. Elsewhere on the yield curve, Doll sees many parts of the fixed income market to end 2014 with negative total rates of return.

• [By Anora Mahmudova]

  The day�� economic data provided a little support. The sales pace of existing homes ticked down in March to the slowest rate since July 2012, according to data released Tuesday, however the decline was smaller than the consensus rate forecast by economists polled by MarketWatch. The SPDR S&P Homebuilder ETF (XHB) �gained 1%.